Silence Therapeutics PLC · NASDAQ:SLN
Silence Therapeutics — Corporate Update (March 2020)
9 slides from Silence Therapeutics's corporate update, Mar 25, 2020
Slide 1: Collaboration with AstraZeneca and R&D update
Silence Therapeutics Collaboration with AstraZeneca and R&D update March 25 2020 © Silence Therapeutics 2019 CONFIDENTIAL 1
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is being supplied and communicated to you solely for your Safe Harbour statement: this presentation may contain forward-looking statements that reflect the Company’s information and may not be reproduced, further distributed to any other pers
Slide 3: Agenda
Agenda • Opening remarks Iain Ross, Executive Chairman • Collaboration with AstraZeneca Iain Ross, Executive Chairman • R&D Update Dr Giles Campion, Head R&D, Chief Medical Officer • Q&A All participants Iain Ross Giles Campion Rob Quinn John Strafford © Silence Therapeutics 2020 3
Slide 4: Collaboration with AstraZeneca for the Treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases
Collaboration with AstraZeneca for the Treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases • Research, Collaboration, Option and Licence agreement to discover and develop RNA interference therapeutics for the treatment of serious diseases. > Draws on Silence’s extensive experience
Slide 5: R&D Update
R&D Update • Re-prioritisation of R&D pipeline due to strengthened balance sheet • SLN360 brought forward as priority asset Preclinical profile of SLN360 in NHP • LP(a) targeting siRNA for cardiovascular disease 1 5 0 L p (a ) • High unmet medical need and excellent preclinical profile le v e ls ± S
Slide 6: Other Recent Highlights from Q1
Other Recent Highlights from Q1 • CEO recruitment progressing well with announcement possible as soon as mid-2020 • Technology Evaluation Agreement with Takeda signed in January 2020 • Scientific Advisory Board formed, to be led by Professor Sir Gordon Duff • World leading scientists and clinicians
Slide 7: Platform validation: putting the pieces in place to unlock value
Platform validation: putting the pieces in place to unlock value SLN360 Middle 2021 July 2019 3. Clinical 1. BD data partnerships SLN124 Jan 2020 H1 2021 Mar 2020 2. Biotech investors © Silence Therapeutics 2020 7
Slide 8: Silence Therapeutics - Summary
Silence Therapeutics - Summary > Reproducible, proprietary gene silencing (RNAi) therapeutics platform, rapidly generating Valuable Platform internal pipeline and out-licensing options. Platform validated through collaborations with HQ in London AstraZeneca, Mallinckrodt and Takeda > SLN360 (CVD wit
Slide 9: Q&A
Q&A © Silence Therapeutics 2020 9